Literature DB >> 3318452

Effects of fibric acid derivatives on biliary lipid composition.

R H Palmer1.   

Abstract

Fenofibrate, a potent analogue of clofibrate, causes changes in biliary lipid composition similar to those seen with clofibrate and other derivatives of fibric acid, although there is a suggestion that the increase in cholesterol content may be accompanied by an increase in phospholipid content as well as a decrease in bile acid content. This may favor liquid crystal formation, and fenofibrate may have less propensity to cause gallstones than would other derivatives. Many other factors are also important in determining whether supersaturated bile will result in gallstone formation, and the use of this compound should be monitored in the future to determine the clinical importance of these findings.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318452     DOI: 10.1016/0002-9343(87)90869-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Fibrates for treatment of the metabolic syndrome.

Authors:  Kevin C Maki
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

2.  Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.

Authors:  I J A M Jonkers; A H M Smelt; M Ledeboer; M E Hollum; I Biemond; F Kuipers; F Stellaard; R Boverhof; A E Meinders; C H B W Lamers; A A M Masclee
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 3.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

4.  Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.

Authors:  F X Caroli-Bosc; P Le Gall; P Pugliese; B Delabre; C Caroli-Bosc; J F Demarquay; J P Delmont; P Rampal; J C Montet
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  Pharmacological effects of lipid-lowering drugs on circulating adipokines.

Authors:  Desiree Wanders; Eric P Plaisance; Robert L Judd
Journal:  World J Diabetes       Date:  2010-09-15

6.  Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.

Authors:  R Raedsch; J Plachky; N Wolf; G Simonis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 7.  A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Authors:  Venkata M Alla; Vrinda Agrawal; Andrew DeNazareth; Syed Mohiuddin; Sudha Ravilla; Marc Rendell
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 8.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.